ClinicalTrials.gg
CompletedNCT03985982BLESSIIIUpdated Jun 5, 2025Results posted

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESSIII)

A Phase 3 interventional study of Botulinum Toxin A and Placebo in Glabellar Frown Lines, sponsored by Croma-Pharma GmbH. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-06-05.

Sponsored by Croma-Pharma GmbH · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
410
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The aim of this study is to assess the efficacy and safety of BoNT/A-DP in the treatment of glabellar lines in comparison with placebo, including efficacy after repeat treatments and long term safety.

Read the detailed description

The study is a parallel-group, randomized, double blind, placebo-controlled study followed by an open label extension.

An interim Analysis will be performed when all subjects finalized the re-evaluation for retreatment visit at week 16 of the first treatment cycle or completed the double blind phase (whichever occurs earlier).

The first treatment cycle of the study will comprise two treatment groups as follows:

  • Group A (active): BoNT/A-DP (20 units, 0.5 mL)
  • Group B (placebo control): sterile, 0.9% sodium chloride, (0.5 mL). Eligible subjects will be randomized at baseline (day 0) to Group A or B to receive the first treatment in a 3:1 randomization scheme, respectively. Investigators and subjects will be blinded to the treatment administered and will evaluate the severity of glabellar lines independently. The subject should perform their assessment independently and ideally before the investigator, to ensure they are not biased by the investigator. The same investigator should assess the subject at baseline and at the visits at weeks 1, 2 and 4 in the first treatment cycle.

After a screening period of up to14 calendar days, subjects will receive the first treatment (BoNT/A-DP or placebo) and attend for visits at 1, 2 and 4 weeks after treatment and at 4 weekly intervals thereafter for evaluation of efficacy and safety (primary and key secondary efficacy endpoints are evaluated in the first treatment cycle in comparison with placebo).

The first treatment cycle will last at least 12 weeks and will end when the subjects qualify for re-treatment (in accordance with the "eligibility for re-treatment criteria"). After the first treatment cycle is completed, all subjects may enter the open label extension phase and will be dosed with BoNT/A-DP (20 U) for subsequent re-treatments.

Evaluation for re-treatment takes place at the earliest at 12 weeks after the first/previous treatment. Subjects who do not qualify for re-treatment at week 12 will have the option (pending eligibility) of re-treatment at a later visit (at 4 weekly intervals thereafter) until they are eligible for re-treatment or until a total of 48 weeks has elapsed since study start. Subjects will attend for visits at 1 and 4 weeks after any re-treatment and at 4 weekly intervals thereafter. At week 2 and week 8 of each open label cycle a telephone call visit will take place. According to the study schedule (Section 2.1 and Section 2.2), a maximum of 4 treatments per subject (4 treatment cycles) is permitted during the study time frame, with treatments separated by a minimum of 12 weeks.

The number of treatments administered per subject will depend on the subject's qualification for re-treatment; however, the last opportunity for re-treatment is at week 48.

02

Conditions studied

  • Glabellar Frown Lines
03

In context

Lead sponsor

Croma-Pharma GmbH is the lead sponsor of 26 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ages ≥ 18 years or older at time of screening (upper limit 75 years, inclusive).
  • Has moderate to severe glabellar frown lines at maximum frown (severity score of 2 or 3 on FWS) as determined by in-clinic assessments by both the investigator and the subject (where: 0 =´none´, 1= ´mild´, 2= ´moderate´, 3= ´severe´).

Subject had a stable medical condition with no uncontrolled systemic disease.

  • Female subjects of had to test negative for pregnancy and agree to use effective during the course of the study.
  • Subjects who wear glasses had to be able to adequately self-assess the severity of their glabellar lines (according to the FWS), without glasses obstructing the forehead area.
  • Moderate to severe glabellar lines indicating an important psychological impact on the subject as indicated by scores > 0 on either the Emotional or the Social Functioning subscale of the Modified Skindex-16 GL-QoL scale.

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with any serotype of botulinum toxin for any indication within the 12 months prior to screening, or any planned treatment with botulinum toxin of any serotype for any reason during the study (other than the treatment).
  • Known to the study drug or its .
  • Any medical condition that may place the subject at increased risk due to exposure to botulinum toxin, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, profound atrophy or weakness in the target muscles, or any other condition (at the investigator´s discretion) that might interfere with neuromuscular function or contraindicate botulinum toxin therapy.
  • Facial laser or light treatment, microdermabrasion, superficial peels or retinoid therapy within the 3 months prior to screening or planned during the study.
  • Apart from the procedures specified above, previous treatment with any facial aesthetic procedure in the glabellar area (including chemical peeling, injection with biodegradable fillers) within 12 months prior to screening or planned during the study.
  • Previous treatment with any serotype of botulinum toxin for any indication within the 12 months prior to screening, or any planned treatment with botulinum toxin of any serotype for any reason during the trail (other than the investigational treatment).
  • Previous insertion of permanent material in the glabellar area or planned during the study.
  • Any surgery, or history of surgery, in the glabellar area including surgical removal of the corrugator, procerus or depressor supercilii muscles or a combination of these or scars in the glabellar area or such surgery planned during the study.
  • Active skin disease/infection or irritation at the treatment area.
  • Inability to substantially lessen glabellar frown lines even by physically spreading them apart.
  • Use of a muscle relaxant within 2 weeks prior to screening, or planned during the study.2
  • Marked facial asymmetry or ptosis of eyelid and/or eyebrow, or current facial palsy or neuromuscular junction disorders as judged by the investigator.
  • Pregnant, breastfeeding or planning to become pregnant during the study.
  • Use of prohibited medication including anticholinergic drugs, or drugs that could interfere with neuromuscular function, including aminoglycoside antibiotics and curare-like compounds within 2 weeks prior to screening or planned during the study.2
  • Planned surgery with general anesthetic (use of local anesthetic outside the glabellar area was permitted).
  • Participation in another clinical study within 1 month of screening and throughout the study.
  • Previous participation in another botulinum toxin aesthetic study which involved the treatment of glabellar lines in combination with canthal lines and/or forehead lines, within the previous 18 months.
  • Chronic drug or alcohol abuse (as per investigator discretion).

Eligibility Criteria for Retreatment

The following criteria had to be met for retreatment:

  • At time of retreatment, the subject did not have relevant changes to their health status from enrolment, which could have prevented the subject's entry into the study according to the inclusion and exclusion criteria.
  • The subject had to have been randomized to receive treatment and must have received ≥ 1 treatment (BoNT/A-DP or placebo).
  • A minimum of 12 weeks must have elapsed since the previous study treatment.
  • The subject's glabellar lines at maximum frown must have to a FWS score of 2 or 3 as determined by both the investigator and the subject.
  • No relevant infection or inflammation in the planned injection area.
  • Negative urine pregnancy test, in women of .
  • The subject had to have received fewer than 4 study treatments.
  • The subject had to have agreed and consented to retreatment.
  • Retreatment was to be performed at the latest by Week 48.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
410 participants (actual)

Study arms

  • Experimental
    Botulinum toxin A

    Botulinum Toxin A will be administered in double blind fashion in cycle 1. 20 Units will be administered (divided in five 0.1 mL i.m injections) into glabellar area.

    Drug: Botulinum Toxin A

  • Placebo comparator
    Placebo

    Placebo will be administered in double blind fashion in cycle 1 divided in five 0.1 mL injections into the glabellar area.

    Drug: Placebo

  • Experimental
    Botulinum toxin A Open Label Extension Arm

    Open Label Extension Arm where all Subjects from Arm 1 and 2 can receive Experimental Treatment in up to 3 treatment cycles. 20 Units will be administered (divided in five 0.1 mL i.m. injections) into the glabellar area.

    Drug: Botulinum Toxin A

Interventions

  • Injection, 20 Units divided in five 0.1 mL i.m injections into the glabellar area

    Also known as: BoNT/A-DP

  • DrugPlacebo

    injection, sodium chloride 0.9 % divided in five 0.1 mL i.m injections into the glabellar area

    Also known as: sodium chloride 0,9 %

  • Injection, 20 Units divided in five 0.1 mL i.m injections into the glabellar area in up to 3 treatment cycles

    Also known as: BoNT/A-DP

06

What researchers measure

Primary outcomes

  1. Facial Wrinkle Scale (FWS) Score of 0 or 1 and an Improvement of ≥ 2 Points in FWS Score (at Maximum Frown) at Week 4 Visit Relative to Baseline, Based on Both the Investigators´ and the Subjects´ In-clinic Assessments.

    The primary endpoint is the percentage of subjects among BoNT/A-DP and placebo groups with a Facial Wrinkle Scale (FWS) score of 0 or 1 and an improvement of ≥ 2 points in FWS score (at maximum frown) at week 4 visit (of the first treatment cycle) relative to baseline (responders), based on both the investigators' and the subjects' in-clinic assessments. Thus, the primary endpoint is a composite endpoint comprising investigator and subject assessments of treatment effectiveness. FWS scores are a four-point rating scale as follows: 0 = no facial wrinkles; 1 = mild facial wrinkles; 2 = moderate facial wrinkles; and 3 = severe facial wrinkles.

    Time frame: Week 4

Secondary outcomes

  1. Extent of Change in Psychological Impact (Emotional and Social Functioning and Concerns Relating to Glabellar Lines)

    Extent of change in psychological impact at week 4 after first treatment, relative to baseline, assessed by * modified Skindex-16 (Glabellar Line Quality of Life Scale, \[GL-QoL\]): Each of 7 items rated on 5-point scale: 0/Never, 1/Rarely, 2/Sometimes, 3/Often, 4/Always bothered, than rescaled to a 0 to 100 standardized score; Emotional Domain is the mean of 4 of the items; Social Functioning Domain is the mean of 3 of the items; Overall score is the mean of all 7 items. All reported scores ranging from 0 (best outcome) to 100 (worst outcome). * validated FACE-Q Appraisal of Lines Between Eyebrows scale: Each of 7 items rated on 4-point scale: 1/Not at all, 2/a little, 3/moderately, 4/extremely. Reported score is the sum of the 7 items, standardized on a scale from 0 (worst outcome) to 100 (best outcome). * Age Appraisal visual analog scale \[VAS\]: Perception of Age compared to actual age, in years ranging from -15 years (best outcome) to +15 years (worst outcome).

    Time frame: Week 4

  2. Percentage of Responders at Maximum Frown at Week 12

    Percentage of subjects among BoNT/A-DP and placebo groups with a Facial Wrinkle Scale (FWS) score of 0 or 1 and an improvement of ≥ 2 points in FWS score (at maximum frown) at week 12 visit (of the first treatment cycle) relative to baseline (responders), based on both the investigators' and the subjects' in-clinic assessments. FWS scores are a four-point rating scale as follows: 0 = no facial wrinkles; 1 = mild facial wrinkles; 2 = moderate facial wrinkles; and 3 = severe facial wrinkles.

    Time frame: Week 12

  3. Percentage of Responders at Week 16

    Percentage of subjects among BoNT/A-DP and placebo groups with a Facial Wrinkle Scale (FWS) score of 0 or 1 and an improvement of ≥ 2 points in FWS score (at maximum frown) at week 16 visit (of the first treatment cycle) relative to baseline (responders), based on both the investigators' and the subjects' in-clinic assessments. FWS scores are a four-point rating scale as follows: 0 = no facial wrinkles; 1 = mild facial wrinkles; 2 = moderate facial wrinkles; and 3 = severe facial wrinkles.

    Time frame: Week 16

  4. Percentage of Responders at Week 20

    Percentage of subjects among BoNT/A-DP and placebo groups with a Facial Wrinkle Scale (FWS) score of 0 or 1 and an improvement of ≥ 2 points in FWS score (at maximum frown) at week 20 visit (of the first treatment cycle) relative to baseline (responders), based on both the investigators' and the subjects' in-clinic assessments. FWS scores are a four-point rating scale as follows: 0 = no facial wrinkles; 1 = mild facial wrinkles; 2 = moderate facial wrinkles; and 3 = severe facial wrinkles.

    Time frame: Week 20

  5. The Percentage of Subjects With a ≥ 1 Point Reduction in Facial Wrinkle Scale (FWS) Score at Rest at Week 4 Based Separately on the Investigators´ and the Subjects´ In-clinic Assessments

    The Percentage of subjects with a ≥ 1 point reduction in Facial Wrinkle Scale (FWS) score at rest at week 4 in the first treatment cycle, based separately on the investigators' and the subjects' in-clinic assessments (applicable only for subjects who have a FWS score at rest ≥ 1 at baseline). FWS scores are a four-point rating scale as follows: 0 = no facial wrinkles; 1 = mild facial wrinkles; 2 = moderate facial wrinkles; and 3 = severe facial wrinkles.

    Time frame: Week 4

  6. Responder Rate at Weeks 1, 2 and 8

    The Percentage of responders among BoNT/A-DP and placebo groups with a Facial Wrinkle Scale (FWS) score at maximum frown of 0 or 1 and an improvement ≥ 2 points in FWS score (at maximum frown) during the first treatment cycle visit relative to baseline, based on both the investigators' and the subjects' in-clinic assessments (composite endpoint, at weeks 1, 2 and 8). FWS scores are a four-point rating scale as follows: 0 = no facial wrinkles; 1 = mild facial wrinkles; 2 = moderate facial wrinkles; and 3 = severe facial wrinkles.

    Time frame: Week 1, Week 2 and Week 8

  7. The Percentage of Subjects With ≥ 2-point and ≥ 1 Reduction in Facial Wrinkle Scale (FWS) Score (at Maximum Frown)

    The percentage of subjects with ≥ 2-point and ≥ 1 reduction in Facial Wrinkle Scale (FWS) score (at maximum frown) in the BoNT/A-DP and placebo groups during the first treatment cycle visit relative to baseline, based on the independent rater's assessment of photographs (at baseline and visits 2, 4, 12, 16 and 20 weeks after treatment, within the first treatment cycle). The median value of all assessments of the same photography was considered for analysis. FWS scores are a four-point rating scale as follows: 0 = no facial wrinkles; 1 = mild facial wrinkles; 2 = moderate facial wrinkles; and 3 = severe facial wrinkles.

    Time frame: Week 2, 4, 12, 16 and 20

  8. Time to Onset of Effect in the BoNT/A-DP and Placebo Groups in the First Treatment Cycle

    Time to onset of effect in the BoNT/A-DP and placebo groups in the first treatment cycle, as measured at weeks 1, 2 and 4 based separately on subject and investigator assessment. Onset of effect defined as at least a 1 point improvement in Facial Wrinkle Scale (FWS) score from baseline (at maximum frown). FWS scores are a four-point rating scale as follows: 0 = no facial wrinkles; 1 = mild facial wrinkles; 2 = moderate facial wrinkles; and 3 = severe facial wrinkles.

    Time frame: From treatment at Day 0 to Week 4 in Treatment Cycle 1

  9. Satisfaction With Treatment, During Each Treatment Cycle, as Assessed by the Validated FACE-Q Satisfaction With Outcome Scale.

    The extent of subject perceptions of effect of, and satisfaction with, treatment in the BoNT/A-DP and placebo groups, during each treatment cycle, as assessed by the validated FACE-Q Satisfaction with Outcome Scale. The FACE-Q Satisfaction with Outcome scale is a patient-reported outcome measure designed to assess a patient's satisfaction with the results of a facial aesthetic procedure. This scale comprises six items, each with four response options: "definitely agree," "somewhat agree," "somewhat disagree," and "definitely disagree."

    Time frame: Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)

  10. The Percentage of Subjects With a ≥ 1 Point Reduction in Facial Wrinkle Scale (FWS) Score at Rest Based on the Independent Rater's Assessment of Photos.

    The percentage of subjects with a ≥ 1 point reduction in Facial Wrinkle Scale (FWS) score at rest in the BoNT/A-DP and placebo groups, relative to baseline, during the first treatment cycle, based on the independent rater's assessment of photos. The median value of all assessments of the same photography was considered for analysis. FWS scores are a four-point rating scale as follows: 0 = no facial wrinkles; 1 = mild facial wrinkles; 2 = moderate facial wrinkles; and 3 = severe facial wrinkles.

    Time frame: Week 2, Week 4, Week 12, Week 16, Week 20 of Treatment Cycle 1

  11. Facial Wrinkle Scale (FWS) Score of 0 or 1 and an Improvement of ≥ 2 Points in FWS Score (at Maximum Frown) at 4 Weeks After Re-treatment Relative to the Rating at the Preceding End-of-Cycle Visit.

    The percentage of subjects with a Facial Wrinkle Scale (FWS) score of 0 or 1 and an improvement of ≥ 2 points in FWS score (at maximum frown) at 4 weeks after re-treatment relative to the rating at the preceding end-of-cycle visit, based on both the investigator's and the subject's in-clinic assessments (composite endpoint). FWS scores are a four-point rating scale as follows: 0 = no facial wrinkles; 1 = mild facial wrinkles; 2 = moderate facial wrinkles; and 3 = severe facial wrinkles.

    Time frame: Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)

  12. The Percentage of Subjects With ≥ 1-point Reduction in Facial Wrinkle Scale (FWS) Score (at Maximum Frown) During the First Treatment Cycle at Week 1, 2, 4, 8, 12, 16 and 20 Relative to Baseline

    The percentage of subjects with ≥ 1-point reduction in Facial Wrinkle Scale (FWS) score (at maximum frown) in the BoNT/A-DP and placebo groups during the first treatment cycle at week 1, 2, 4, 8, 12, 16 and 20 relative to baseline, based on both the investigators' and the subjects' in-clinic assessments (composite endpoint). For week 16 and 20 subjects who were re-treated before the respective visits were counted as non-responders. FWS scores are a four-point rating scale as follows: 0 = no facial wrinkles; 1 = mild facial wrinkles; 2 = moderate facial wrinkles; and 3 = severe facial wrinkles.

    Time frame: Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20 of Treatment Cycle 1

  13. The Percentage of Subjects With ≥ 1-point Reduction in Facial Wrinkle Scale (FWS) Score (at Maximum Frown) During Each Re-treatment Cycle at Week 4 Relative to Re-treatment-baseline.

    The percentage of subjects with ≥ 1-point reduction in Facial Wrinkle Scale (FWS) score (at maximum frown) in the BoNT/A-DP during each re-treatment cycle at week 4 relative to re-treatment baseline, based on both the investigators' and the subjects' in-clinic assessments (composite endpoint). FWS scores are a four-point rating scale as follows: 0 = no facial wrinkles; 1 = mild facial wrinkles; 2 = moderate facial wrinkles; and 3 = severe facial wrinkles.

    Time frame: Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)

  14. Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious AEs (SAEs) and AEs of Special Interest (AESIs)

    Number of Participants with treatment-emergent adverse events (TEAEs), serious AEs (SAEs) and AEs of special interest (AESIs)

    Time frame: Through study completion (60 weeks)

  15. Number of Participants With Neutralizing Anti-Drug Antibodies

    Number of Participants with Neutralizing Anti-Drug Antibodies Antibody formation, evaluation pre-dose before each treatment, at 4 weeks after each treatment and at the final study visit.

    Time frame: Through study completion (60 weeks)

  16. Change From Baseline of Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets

    Safety assessments by evaluating change from baseline of Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets as per the study schedule

    Time frame: Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)

  17. Change From Baseline of Alanine Aminotransferase, Alkaline Phosphatase , Aspartate Aminotransferase, Gamma Glutamyl Transpeptidase

    Safety assessments by evaluating change from baseline of Alanine Aminotransferase, Alkaline Phosphatase , Aspartate Aminotransferase, Gamma Glutamyl Transpeptidase as per the study schedule

    Time frame: Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)

  18. Change From Baseline of Cholesterol, Glucose, Potassium, Sodium, Urea Nitrogen

    Safety assessments by evaluating change from baseline of Cholesterol, Glucose, Potassium, Sodium, Urea Nitrogen as per the study schedule

    Time frame: Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)

  19. Change From to Baseline of Bilirubin, Creatinin

    Safety assessments by evaluating change from baseline of Bilirubin, Creatinin as per the study schedule

    Time frame: Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)

  20. Change From Baseline of Erythrocytes

    Safety assessments by evaluating change from baseline of Erythrocytes as per the study schedule

    Time frame: Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)

  21. Change From Baseline of Erythrocytes MCV

    Safety assessments by evaluating change from baseline of Erythrocytes MCV as per the study schedule

    Time frame: Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)

  22. Change From Baseline of Erythrocyte MCHC, Hemoglobin

    Safety assessments by evaluating change from baseline of Erythrocyte MCHC, Hemoglobin as per the study schedule

    Time frame: Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)

  23. Change From Baseline of Lymphocytes/Leukocytes, Monocytes/Leukocytes, Neutrophils/Leukocytes, Basophiles/Leukocytes, Eosinophils/Leukocytes

    Safety assessments by evaluating change from baseline of Lymphocytes/leukocytes, Monocytes/leukocytes, Neutrophils/leukocytes, Basophiles/leukocytes, Eosinophils/leukocytes as per the study schedule

    Time frame: Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)

  24. Change From Baseline of Systolic and Diastolic Blood Pressure

    Safety assessments by evaluating change from baseline of Systolic and Diastolic Blood Pressure as per the study schedule

    Time frame: Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)

  25. Change From Baseline of Pulse Rate

    Safety assessments by evaluating change from baseline of Pulse rate as per the study schedule

    Time frame: Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)

  26. Number of Participants With Normal and Abnormal Electrocardiogram

    Safety assessments by evaluating Electrocardiogram as per the study schedule

    Time frame: Week 4 and last visit of Treatment Cycle 1 (End of Cycle procedures), conducted upon confirmation of eligibility for retreatment, assessed starting 12 weeks post-treatment with 4-weekly evaluations up to a max. of 48 weeks post treatment.

07

Results

Posted Jun 5, 2025

Participant flow

Double-Blind Phase
Participant flow — Double-Blind Phase
MilestoneBotulinum Toxin APlaceboBotulinum Toxin A Open Label Extension Arm
Started266890
Completed250840
Not completed1650
Withdrew: Lost to follow-up430
Withdrew: Physician decision100
Withdrew: Withdrawal by subject920
Withdrew: Covid-19100
Withdrew: Early termination due to botox injection while participating in the study100
Open-Label Phase
Participant flow — Open-Label Phase
MilestoneBotulinum Toxin APlaceboBotulinum Toxin A Open Label Extension Arm
Started00323
Completed00297
Not completed0026
Withdrew: Lost to follow-up0013
Withdrew: Physician decision002
Withdrew: Withdrawal by subject0011

Outcome measures

PrimaryFacial Wrinkle Scale (FWS) Score of 0 or 1 and an Improvement of ≥ 2 Points in FWS Score (at Maximum Frown) at Week 4 Visit Relative to Baseline, Based on Both the Investigators´ and the Subjects´ In-clinic Assessments.

The primary endpoint is the percentage of subjects among BoNT/A-DP and placebo groups with a Facial Wrinkle Scale (FWS) score of 0 or 1 and an improvement of ≥ 2 points in FWS score (at maximum frown) at week 4 visit (of the first treatment cycle) relative to baseline (responders), based on both the investigators' and the subjects' in-clinic assessments. Thus, the primary endpoint is a composite endpoint comprising investigator and subject assessments of treatment effectiveness. FWS scores are a four-point rating scale as follows: 0 = no facial wrinkles; 1 = mild facial wrinkles; 2 = moderate facial wrinkles; and 3 = severe facial wrinkles.

Time frame:
Week 4
Reported as:
Count of participants · Participants
Facial Wrinkle Scale (FWS) Score of 0 or 1 and an Improvement of ≥ 2 Points in FWS Score (at Maximum Frown) at Week 4 Visit Relative to Baseline, Based on Both the Investigators´ and the Subjects´ In-clinic Assessments.
ParticipantsBotulinum Toxin APlacebo
Facial Wrinkle Scale (FWS) Score of 0 or 1 and an Improvement of ≥ 2 Points in FWS Score (at Maximum Frown) at Week 4 Visit Relative to Baseline, Based on Both the Investigators´ and the Subjects´ In-clinic Assessments.1720
Statistical analysis
  • Botulinum Toxin A vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 (This outcome measure is the first to be assessed in a hierarchical testing sequence using a one-sided alpha of 0.025.)
SecondaryExtent of Change in Psychological Impact (Emotional and Social Functioning and Concerns Relating to Glabellar Lines)

Extent of change in psychological impact at week 4 after first treatment, relative to baseline, assessed by * modified Skindex-16 (Glabellar Line Quality of Life Scale, \[GL-QoL\]): Each of 7 items rated on 5-point scale: 0/Never, 1/Rarely, 2/Sometimes, 3/Often, 4/Always bothered, than rescaled to a 0 to 100 standardized score; Emotional Domain is the mean of 4 of the items; Social Functioning Domain is the mean of 3 of the items; Overall score is the mean of all 7 items. All reported scores ranging from 0 (best outcome) to 100 (worst outcome). * validated FACE-Q Appraisal of Lines Between Eyebrows scale: Each of 7 items rated on 4-point scale: 1/Not at all, 2/a little, 3/moderately, 4/extremely. Reported score is the sum of the 7 items, standardized on a scale from 0 (worst outcome) to 100 (best outcome). * Age Appraisal visual analog scale \[VAS\]: Perception of Age compared to actual age, in years ranging from -15 years (best outcome) to +15 years (worst outcome).

Time frame:
Week 4
Reported as:
Mean · score on a scale
Extent of Change in Psychological Impact (Emotional and Social Functioning and Concerns Relating to Glabellar Lines)
score on a scaleBotulinum Toxin APlacebo
Modified Skindex-16 (GL-QoL) Emotional domain - Change from Baseline at Week 4-42.27 ± 34.4840.50 ± 20.427
Modified Skindex-16 (GL-QoL) Social Functioning domain - Change from Baseline at Week 4-33.14 ± 33.193-2.23 ± 31.088
Modified Skindex-16 (GL-QoL) Overall score - Change from Baseline at Week 4-38.35 ± 31.075-0.67 ± 22.369
FACE-Q Appraisal of Lines Between Eyebrows - Change from Baseline at Week 446.4 ± 28.62-2.9 ± 21.60
Age Appraisal VAS - Change from Baseline at Week 4-2.3 ± 4.20-0.2 ± 3.42
Statistical analysis
  • Botulinum Toxin A vs Placebo · Wilcoxon (Mann-Whitney) · p = <0.001 (The statistical significance is set to 0.025. This is the second test in a hierarchical testing sequence. Statistical significance will only be assessed if the previous test shows statistical significance at the 1-sided alpha level of 0.025.)
  • Botulinum Toxin A vs Placebo · Wilcoxon (Mann-Whitney) · p = <0.001 (The statistical significance is set to 0.025. This is the third test in a hierarchical testing sequence. Statistical significance will only be assessed if the previous two tests show statistical significance at the alpha level of 0.025.)
  • Botulinum Toxin A vs Placebo · Wilcoxon (Mann-Whitney) · p = <0.001 (The statistical significance is set to 0.025. This is the forth test in a hierarchical testing sequence. Statistical significance will only be assessed if the previous three tests show statistical significance at the 1-sided alpha level of 0.025.)
  • Botulinum Toxin A vs Placebo · Wilcoxon (Mann-Whitney) · p = <0.001 (The statistical significance is set to 0.025. This is the fifth test in a hierarchical testing sequence. Statistical significance will only be assessed if the previous four tests show statistical significance at the 1-sided alpha level of 0.025.)
  • Botulinum Toxin A vs Placebo · Wilcoxon (Mann-Whitney) · p = <0.001 (The statistical significance is set to 0.025. This is the sixth test in a hierarchical testing sequence. Statistical significance will only be assessed if the previous five tests show statistical significance at the 1-sided alpha level of 0.025.)
SecondaryPercentage of Responders at Maximum Frown at Week 12

Percentage of subjects among BoNT/A-DP and placebo groups with a Facial Wrinkle Scale (FWS) score of 0 or 1 and an improvement of ≥ 2 points in FWS score (at maximum frown) at week 12 visit (of the first treatment cycle) relative to baseline (responders), based on both the investigators' and the subjects' in-clinic assessments. FWS scores are a four-point rating scale as follows: 0 = no facial wrinkles; 1 = mild facial wrinkles; 2 = moderate facial wrinkles; and 3 = severe facial wrinkles.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Percentage of Responders at Maximum Frown at Week 12
ParticipantsBotulinum Toxin APlacebo
Percentage of Responders at Maximum Frown at Week 12561
SecondaryPercentage of Responders at Week 16

Percentage of subjects among BoNT/A-DP and placebo groups with a Facial Wrinkle Scale (FWS) score of 0 or 1 and an improvement of ≥ 2 points in FWS score (at maximum frown) at week 16 visit (of the first treatment cycle) relative to baseline (responders), based on both the investigators' and the subjects' in-clinic assessments. FWS scores are a four-point rating scale as follows: 0 = no facial wrinkles; 1 = mild facial wrinkles; 2 = moderate facial wrinkles; and 3 = severe facial wrinkles.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Percentage of Responders at Week 16
ParticipantsBotulinum Toxin APlacebo
Percentage of Responders at Week 16271
SecondaryPercentage of Responders at Week 20

Percentage of subjects among BoNT/A-DP and placebo groups with a Facial Wrinkle Scale (FWS) score of 0 or 1 and an improvement of ≥ 2 points in FWS score (at maximum frown) at week 20 visit (of the first treatment cycle) relative to baseline (responders), based on both the investigators' and the subjects' in-clinic assessments. FWS scores are a four-point rating scale as follows: 0 = no facial wrinkles; 1 = mild facial wrinkles; 2 = moderate facial wrinkles; and 3 = severe facial wrinkles.

Time frame:
Week 20
Reported as:
Count of participants · Participants
Percentage of Responders at Week 20
ParticipantsBotulinum Toxin APlacebo
Percentage of Responders at Week 2050
SecondaryThe Percentage of Subjects With a ≥ 1 Point Reduction in Facial Wrinkle Scale (FWS) Score at Rest at Week 4 Based Separately on the Investigators´ and the Subjects´ In-clinic Assessments

The Percentage of subjects with a ≥ 1 point reduction in Facial Wrinkle Scale (FWS) score at rest at week 4 in the first treatment cycle, based separately on the investigators' and the subjects' in-clinic assessments (applicable only for subjects who have a FWS score at rest ≥ 1 at baseline). FWS scores are a four-point rating scale as follows: 0 = no facial wrinkles; 1 = mild facial wrinkles; 2 = moderate facial wrinkles; and 3 = severe facial wrinkles.

Time frame:
Week 4
Reported as:
Count of participants · Participants
The Percentage of Subjects With a ≥ 1 Point Reduction in Facial Wrinkle Scale (FWS) Score at Rest at Week 4 Based Separately on the Investigators´ and the Subjects´ In-clinic Assessments
ParticipantsBotulinum Toxin APlacebo
Investigator's In-clinic Assessment1638
Subject's In-clinic Assessment21411
SecondaryResponder Rate at Weeks 1, 2 and 8

The Percentage of responders among BoNT/A-DP and placebo groups with a Facial Wrinkle Scale (FWS) score at maximum frown of 0 or 1 and an improvement ≥ 2 points in FWS score (at maximum frown) during the first treatment cycle visit relative to baseline, based on both the investigators' and the subjects' in-clinic assessments (composite endpoint, at weeks 1, 2 and 8). FWS scores are a four-point rating scale as follows: 0 = no facial wrinkles; 1 = mild facial wrinkles; 2 = moderate facial wrinkles; and 3 = severe facial wrinkles.

Time frame:
Week 1, Week 2 and Week 8
Reported as:
Count of participants · Participants
Responder Rate at Weeks 1, 2 and 8
ParticipantsBotulinum Toxin APlacebo
Week 11500
Week 21890
Week 81290
SecondaryThe Percentage of Subjects With ≥ 2-point and ≥ 1 Reduction in Facial Wrinkle Scale (FWS) Score (at Maximum Frown)

The percentage of subjects with ≥ 2-point and ≥ 1 reduction in Facial Wrinkle Scale (FWS) score (at maximum frown) in the BoNT/A-DP and placebo groups during the first treatment cycle visit relative to baseline, based on the independent rater's assessment of photographs (at baseline and visits 2, 4, 12, 16 and 20 weeks after treatment, within the first treatment cycle). The median value of all assessments of the same photography was considered for analysis. FWS scores are a four-point rating scale as follows: 0 = no facial wrinkles; 1 = mild facial wrinkles; 2 = moderate facial wrinkles; and 3 = severe facial wrinkles.

Time frame:
Week 2, 4, 12, 16 and 20
Reported as:
Count of participants · Participants
The Percentage of Subjects With ≥ 2-point and ≥ 1 Reduction in Facial Wrinkle Scale (FWS) Score (at Maximum Frown)
ParticipantsBotulinum Toxin APlacebo
≥ 2-point reduction - Week 21500
≥ 2-point reduction - Week 41440
≥ 2-point reduction - Week 12111
≥ 2-point reduction - Week 1640
≥ 2-point reduction - Week 2020
≥ 1-point reduction - Week 22356
≥ 1-point reduction - Week 42349
≥ 1-point reduction - Week 12715
≥ 1-point reduction - Week 16290
≥ 1-point reduction - Week 20211
SecondaryTime to Onset of Effect in the BoNT/A-DP and Placebo Groups in the First Treatment Cycle

Time to onset of effect in the BoNT/A-DP and placebo groups in the first treatment cycle, as measured at weeks 1, 2 and 4 based separately on subject and investigator assessment. Onset of effect defined as at least a 1 point improvement in Facial Wrinkle Scale (FWS) score from baseline (at maximum frown). FWS scores are a four-point rating scale as follows: 0 = no facial wrinkles; 1 = mild facial wrinkles; 2 = moderate facial wrinkles; and 3 = severe facial wrinkles.

Time frame:
From treatment at Day 0 to Week 4 in Treatment Cycle 1
Reported as:
Median · Days
Time to Onset of Effect in the BoNT/A-DP and Placebo Groups in the First Treatment Cycle
DaysBotulinum Toxin APlacebo
Time to Onset of Effect in the BoNT/A-DP and Placebo Groups in the First Treatment Cycle8 (8 to 9)NA (NA to NA)
SecondarySatisfaction With Treatment, During Each Treatment Cycle, as Assessed by the Validated FACE-Q Satisfaction With Outcome Scale.

The extent of subject perceptions of effect of, and satisfaction with, treatment in the BoNT/A-DP and placebo groups, during each treatment cycle, as assessed by the validated FACE-Q Satisfaction with Outcome Scale. The FACE-Q Satisfaction with Outcome scale is a patient-reported outcome measure designed to assess a patient's satisfaction with the results of a facial aesthetic procedure. This scale comprises six items, each with four response options: "definitely agree," "somewhat agree," "somewhat disagree," and "definitely disagree."

Time frame:
Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)
Reported as:
Count of participants · Participants
Satisfaction With Treatment, During Each Treatment Cycle, as Assessed by the Validated FACE-Q Satisfaction With Outcome Scale.
ParticipantsBotulinum Toxin APlaceboBotulinum Toxin A Open Label Extension Arm
Cycle 1 Week 4 - pleased — Definitely disagree1678—
Cycle 1 Week 4 - pleased — Somewhat disagree133—
Cycle 1 Week 4 - pleased — Somewhat agree464—
Cycle 1 Week 4 - pleased — Definitely agree1891—
Cycle 1 Week 4 - pleased — Missing23—
Cycle 1 Week 4 - expected — Definitely disagree1774—
Cycle 1 Week 4 - expected — Somewhat disagree277—
Cycle 1 Week 4 - expected — Somewhat agree695—
Cycle 1 Week 4 - expected — Definitely agree1510—
Cycle 1 Week 4 - expected — Missing23—
Cycle 1 Week 4 - great — Definitely disagree2377—
Cycle 1 Week 4 - great — Somewhat disagree207—
Cycle 1 Week 4 - great — Somewhat agree582—
Cycle 1 Week 4 - great — Definitely agree1630—
Cycle 1 Week 4 - great — Missing23—
Cycle 1 Week 4 - look in the mirror — Definitely disagree1874—
Cycle 1 Week 4 - look in the mirror — Somewhat disagree3410—
Cycle 1 Week 4 - look in the mirror — Somewhat agree1012—
Cycle 1 Week 4 - look in the mirror — Definitely agree1110—
Cycle 1 Week 4 - look in the mirror — Missing23—
Cycle 1 Week 4 - fantastic — Definitely disagree2578—
Cycle 1 Week 4 - fantastic — Somewhat disagree317—
Cycle 1 Week 4 - fantastic — Somewhat agree741—
Cycle 1 Week 4 - fantastic — Definitely agree1340—
Cycle 1 Week 4 - fantastic — Missing23—
Cycle 1 Week 4 - miraculous — Definitely disagree3178—
Cycle 1 Week 4 - miraculous — Somewhat disagree468—
Cycle 1 Week 4 - miraculous — Somewhat agree880—
Cycle 1 Week 4 - miraculous — Definitely agree990—
Cycle 1 Week 4 - miraculous — Missing23—
Cycle 2 Week 4 - pleased — Definitely disagree——17
Cycle 2 Week 4 - pleased — Somewhat disagree——20
Cycle 2 Week 4 - pleased — Somewhat agree——75
Cycle 2 Week 4 - pleased — Definitely agree——200
Cycle 2 Week 4 - pleased — Missing——11
Cycle 2 Week 4 - expected — Definitely disagree——24
Cycle 2 Week 4 - expected — Somewhat disagree——34
Cycle 2 Week 4 - expected — Somewhat agree——78
Cycle 2 Week 4 - expected — Definitely agree——176
Cycle 2 Week 4 - expected — Missing——11
Cycle 2 Week 4 - great — Definitely disagree——30
Cycle 2 Week 4 - great — Somewhat disagree——23
Cycle 2 Week 4 - great — Somewhat agree——80
Cycle 2 Week 4 - great — Definitely agree——179
Cycle 2 Week 4 - great — Missing——11
Cycle 2 Week 4 - look in the mirror — Definitely disagree——25
Cycle 2 Week 4 - look in the mirror — Somewhat disagree——47
Cycle 2 Week 4 - look in the mirror — Somewhat agree——111
Cycle 2 Week 4 - look in the mirror — Definitely agree——129
Cycle 2 Week 4 - look in the mirror — Missing——11
Cycle 2 Week 4 - fantastic — Definitely disagree——36
Cycle 2 Week 4 - fantastic — Somewhat disagree——46
Cycle 2 Week 4 - fantastic — Somewhat agree——90
Cycle 2 Week 4 - fantastic — Definitely agree——140
Cycle 2 Week 4 - fantastic — Missing——11
Cycle 2 Week 4 - miraculous — Definitely disagree——52
Cycle 2 Week 4 - miraculous — Somewhat disagree——53
Cycle 2 Week 4 - miraculous — Somewhat agree——105
Cycle 2 Week 4 - miraculous — Definitely agree——102
Cycle 2 Week 4 - miraculous — Missing——11
Cycle 3 Week 4 - pleased — Definitely disagree——16
Cycle 3 Week 4 - pleased — Somewhat disagree——19
Cycle 3 Week 4 - pleased — Somewhat agree——60
Cycle 3 Week 4 - pleased — Definitely agree——166
Cycle 3 Week 4 - pleased — Missing——4
Cycle 3 Week 4 - expected — Definitely disagree——20
Cycle 3 Week 4 - expected — Somewhat disagree——23
Cycle 3 Week 4 - expected — Somewhat agree——62
Cycle 3 Week 4 - expected — Definitely agree——156
Cycle 3 Week 4 - expected — Missing——4
Cycle 3 Week 4 - great — Definitely disagree——24
Cycle 3 Week 4 - great — Somewhat disagree——30
Cycle 3 Week 4 - great — Somewhat agree——56
Cycle 3 Week 4 - great — Definitely agree——151
Cycle 3 Week 4 - great — Missing——4
Cycle 3 Week 4 - look in the mirror — Definitely disagree——26
Cycle 3 Week 4 - look in the mirror — Somewhat disagree——31
Cycle 3 Week 4 - look in the mirror — Somewhat agree——100
Cycle 3 Week 4 - look in the mirror — Definitely agree——104
Cycle 3 Week 4 - look in the mirror — Missing——4
Cycle 3 Week 4 - fantastic — Definitely disagree——35
Cycle 3 Week 4 - fantastic — Somewhat disagree——31
Cycle 3 Week 4 - fantastic — Somewhat agree——72
Cycle 3 Week 4 - fantastic — Definitely agree——123
Cycle 3 Week 4 - fantastic — Missing——4
Cycle 3 Week 4 - miraculous — Definitely disagree——52
Cycle 3 Week 4 - miraculous — Somewhat disagree——34
Cycle 3 Week 4 - miraculous — Somewhat agree——77
Cycle 3 Week 4 - miraculous — Definitely agree——98
Cycle 3 Week 4 - miraculous — Missing——4
Cycle 4 Week 4 - pleased — Definitely disagree——12
Cycle 4 Week 4 - pleased — Somewhat disagree——6
Cycle 4 Week 4 - pleased — Somewhat agree——37
Cycle 4 Week 4 - pleased — Definitely agree——83
Cycle 4 Week 4 - pleased — Missing——1
Cycle 4 Week 4 - expected — Definitely disagree——10
Cycle 4 Week 4 - expected — Somewhat disagree——17
Cycle 4 Week 4 - expected — Somewhat agree——34
Cycle 4 Week 4 - expected — Definitely agree——77
Cycle 4 Week 4 - expected — Missing——1
Cycle 4 Week 4 - great — Definitely disagree——17
Cycle 4 Week 4 - great — Somewhat disagree——16
Cycle 4 Week 4 - great — Somewhat agree——33
Cycle 4 Week 4 - great — Definitely agree——72
Cycle 4 Week 4 - great — Missing——1
Cycle 4 Week 4 - look in the mirror — Definitely disagree——15
Cycle 4 Week 4 - look in the mirror — Somewhat disagree——18
Cycle 4 Week 4 - look in the mirror — Somewhat agree——55
Cycle 4 Week 4 - look in the mirror — Definitely agree——50
Cycle 4 Week 4 - look in the mirror — Missing——1
Cycle 4 Week 4 - fantastic — Definitely disagree——21
Cycle 4 Week 4 - fantastic — Somewhat disagree——16
Cycle 4 Week 4 - fantastic — Somewhat agree——46
Cycle 4 Week 4 - fantastic — Definitely agree——55
Cycle 4 Week 4 - fantastic — Missing——1
Cycle 4 Week 4 - miraculous — Definitely disagree——29
Cycle 4 Week 4 - miraculous — Somewhat disagree——23
Cycle 4 Week 4 - miraculous — Somewhat agree——45
Cycle 4 Week 4 - miraculous — Definitely agree——41
Cycle 4 Week 4 - miraculous — Missing——1
SecondaryThe Percentage of Subjects With a ≥ 1 Point Reduction in Facial Wrinkle Scale (FWS) Score at Rest Based on the Independent Rater's Assessment of Photos.

The percentage of subjects with a ≥ 1 point reduction in Facial Wrinkle Scale (FWS) score at rest in the BoNT/A-DP and placebo groups, relative to baseline, during the first treatment cycle, based on the independent rater's assessment of photos. The median value of all assessments of the same photography was considered for analysis. FWS scores are a four-point rating scale as follows: 0 = no facial wrinkles; 1 = mild facial wrinkles; 2 = moderate facial wrinkles; and 3 = severe facial wrinkles.

Time frame:
Week 2, Week 4, Week 12, Week 16, Week 20 of Treatment Cycle 1
Reported as:
Count of participants · Participants
The Percentage of Subjects With a ≥ 1 Point Reduction in Facial Wrinkle Scale (FWS) Score at Rest Based on the Independent Rater's Assessment of Photos.
ParticipantsBotulinum Toxin APlacebo
Week 21069
Week 410013
Week 12378
Week 16210
Week 20111
SecondaryFacial Wrinkle Scale (FWS) Score of 0 or 1 and an Improvement of ≥ 2 Points in FWS Score (at Maximum Frown) at 4 Weeks After Re-treatment Relative to the Rating at the Preceding End-of-Cycle Visit.

The percentage of subjects with a Facial Wrinkle Scale (FWS) score of 0 or 1 and an improvement of ≥ 2 points in FWS score (at maximum frown) at 4 weeks after re-treatment relative to the rating at the preceding end-of-cycle visit, based on both the investigator's and the subject's in-clinic assessments (composite endpoint). FWS scores are a four-point rating scale as follows: 0 = no facial wrinkles; 1 = mild facial wrinkles; 2 = moderate facial wrinkles; and 3 = severe facial wrinkles.

Time frame:
Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)
Reported as:
Count of participants · Participants
Facial Wrinkle Scale (FWS) Score of 0 or 1 and an Improvement of ≥ 2 Points in FWS Score (at Maximum Frown) at 4 Weeks After Re-treatment Relative to the Rating at the Preceding End-of-Cycle Visit.
ParticipantsBotulinum Toxin A Open Label Extension Arm
Week 4 after 1st Re-treatment153
Week 4 after 2nd Re-treatment119
Week 4 after 3rd Re-treatment43
SecondaryThe Percentage of Subjects With ≥ 1-point Reduction in Facial Wrinkle Scale (FWS) Score (at Maximum Frown) During the First Treatment Cycle at Week 1, 2, 4, 8, 12, 16 and 20 Relative to Baseline

The percentage of subjects with ≥ 1-point reduction in Facial Wrinkle Scale (FWS) score (at maximum frown) in the BoNT/A-DP and placebo groups during the first treatment cycle at week 1, 2, 4, 8, 12, 16 and 20 relative to baseline, based on both the investigators' and the subjects' in-clinic assessments (composite endpoint). For week 16 and 20 subjects who were re-treated before the respective visits were counted as non-responders. FWS scores are a four-point rating scale as follows: 0 = no facial wrinkles; 1 = mild facial wrinkles; 2 = moderate facial wrinkles; and 3 = severe facial wrinkles.

Time frame:
Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20 of Treatment Cycle 1
Reported as:
Count of participants · Participants
The Percentage of Subjects With ≥ 1-point Reduction in Facial Wrinkle Scale (FWS) Score (at Maximum Frown) During the First Treatment Cycle at Week 1, 2, 4, 8, 12, 16 and 20 Relative to Baseline
ParticipantsBotulinum Toxin APlacebo
Week 12202
Week 22340
Week 42360
Week 82131
Week 121622
Week 16941
Week 20460
SecondaryThe Percentage of Subjects With ≥ 1-point Reduction in Facial Wrinkle Scale (FWS) Score (at Maximum Frown) During Each Re-treatment Cycle at Week 4 Relative to Re-treatment-baseline.

The percentage of subjects with ≥ 1-point reduction in Facial Wrinkle Scale (FWS) score (at maximum frown) in the BoNT/A-DP during each re-treatment cycle at week 4 relative to re-treatment baseline, based on both the investigators' and the subjects' in-clinic assessments (composite endpoint). FWS scores are a four-point rating scale as follows: 0 = no facial wrinkles; 1 = mild facial wrinkles; 2 = moderate facial wrinkles; and 3 = severe facial wrinkles.

Time frame:
Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)
Reported as:
Count of participants · Participants
The Percentage of Subjects With ≥ 1-point Reduction in Facial Wrinkle Scale (FWS) Score (at Maximum Frown) During Each Re-treatment Cycle at Week 4 Relative to Re-treatment-baseline.
ParticipantsBotulinum Toxin A Open Label Extension Arm
Week 4 after 1st Re-treatment267
Week 4 after 2nd Re-treatment210
Week 4 after 3rd Re-treatment104
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs), Serious AEs (SAEs) and AEs of Special Interest (AESIs)

Number of Participants with treatment-emergent adverse events (TEAEs), serious AEs (SAEs) and AEs of special interest (AESIs)

Time frame:
Through study completion (60 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious AEs (SAEs) and AEs of Special Interest (AESIs)
ParticipantsBotulinum Toxin APlaceboBotulinum Toxin A Open Label Extension Arm
Subjects with any Treatment Emergent Adverse Event (TEAE)481480
Subjects with any Study Medication Related TEAE408
Subjects with any Injection Procedure Related TEAE406
Subjects with any Severe TEAE103
Subjects with severe study drug related TEAE000
Subjects with severe injection procedure related TEAE000
Subjects with any Serious TEAE114
Subjects with any Adverse Events of Special Interest (AESI)107
Subjects with any TEAE leading to discontinuation000
SecondaryNumber of Participants With Neutralizing Anti-Drug Antibodies

Number of Participants with Neutralizing Anti-Drug Antibodies Antibody formation, evaluation pre-dose before each treatment, at 4 weeks after each treatment and at the final study visit.

Time frame:
Through study completion (60 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Neutralizing Anti-Drug Antibodies
ParticipantsBotulinum Toxin APlaceboBotulinum Toxin A Open Label Extension Arm
Baseline - Anti-Drug Antibodies (ADA) Screening Assay - Reactive234—
Baseline - ADA Confirmation Assay - Confirmed00—
End of Study - ADA Screening Assay - Reactive0021
End of Study - ADA Confirmation Assay - Confirmed000
SecondaryChange From Baseline of Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets

Safety assessments by evaluating change from baseline of Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets as per the study schedule

Time frame:
Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)
Reported as:
Mean · x10^9 cells/L
Change From Baseline of Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets
x10^9 cells/LBotulinum Toxin APlaceboBotulinum Toxin A Open Label Extension Arm
Week 4 of cycle 1 - Basophils (x10^9 cells/L)0.004 ± 0.04130.012 ± 0.0556—
Week 4 of cycle 1 - Eosinophils (x10^9 cells/L)0.006 ± 0.07260.007 ± 0.0767—
Week 4 of cycle 1 - Leukocytes (x10^9 cells/L)-0.029 ± 1.49250.227 ± 1.4308—
Week 4 of cycle 1 - Lymphocytes (x10^9 cells/L)-0.038 ± 0.4554-0.027 ± 0.4222—
Week 4 of cycle 1 - Monocytes (x10^9 cells/L)-0.027 ± 0.1607-0.019 ± 0.2154—
Week 4 of cycle 1 - Neutrophils (x10^9 cells/L)0.027 ± 1.32110.252 ± 1.1477—
Week 4 of cycle 1 - Platelets (x10^9 cells/L)0.3 ± 37.31-0.8 ± 38.87—
Week 4 of cycle 2 - Basophils (x10^9 cells/L)——-0.002 ± 0.0565
Week 4 of cycle 2 - Eosinophils (x10^9 cells/L)——0.009 ± 0.0998
Week 4 of cycle 2 - Leukocytes (x10^9 cells/L)——0.000 ± 1.5182
Week 4 of cycle 2 - Lymphocytes (x10^9 cells/L)——0.043 ± 0.4282
Week 4 of cycle 2 - Monocytes (x10^9 cells/L)——-0.002 ± 0.1123
Week 4 of cycle 2 - Neutrophils (x10^9 cells/L)——-0.048 ± 1.3470
Week 4 of cycle 2 - Platelets (x10^9 cells/L)——6.1 ± 37.89
Week 4 of cycle 3 - Basophils (x10^9 cells/L)——-0.018 ± 0.0496
Week 4 of cycle 3 - Eosinophils (x10^9 cells/L)——-0.002 ± 0.1059
Week 4 of cycle 3 - Leukocytes (x10^9 cells/L)——-0.050 ± 2.0753
Week 4 of cycle 3 - Lymphocytes (x10^9 cells/L)——0.021 ± 0.4473
Week 4 of cycle 3 - Monocytes (x10^9 cells/L)——-0.018 ± 0.1246
Week 4 of cycle 3 - Neutrophils (x10^9 cells/L)——-0.034 ± 1.9383
Week 4 of cycle 3 - Platelets (x10^9 cells/L)——6.1 ± 39.16
Week 4 of cycle 4 - Basophils (x10^9 cells/L)——-0.019 ± 0.0475
Week 4 of cycle 4 - Eosinophils (x10^9 cells/L)——-0.026 ± 0.0859
Week 4 of cycle 4 - Leukocytes (x10^9 cells/L)——-0.404 ± 1.5800
Week 4 of cycle 4 - Lymphocytes (x10^9 cells/L)——0.003 ± 0.4665
Week 4 of cycle 4 - Monocytes (x10^9 cells/L)——-0.025 ± 0.1698
Week 4 of cycle 4 - Neutrophils (x10^9 cells/L)——-0.344 ± 1.3644
Week 4 of cycle 4 - Platelets (x10^9 cells/L)——0.4 ± 41.64
SecondaryChange From Baseline of Alanine Aminotransferase, Alkaline Phosphatase , Aspartate Aminotransferase, Gamma Glutamyl Transpeptidase

Safety assessments by evaluating change from baseline of Alanine Aminotransferase, Alkaline Phosphatase , Aspartate Aminotransferase, Gamma Glutamyl Transpeptidase as per the study schedule

Time frame:
Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)
Reported as:
Mean · U/L
Change From Baseline of Alanine Aminotransferase, Alkaline Phosphatase , Aspartate Aminotransferase, Gamma Glutamyl Transpeptidase
U/LBotulinum Toxin APlaceboBotulinum Toxin A Open Label Extension Arm
Week 4 of cycle 1 - Alanine Aminotransferase (U/L)-0.1 ± 9.321.9 ± 19.35—
Week 4 of cycle 1 - Alkaline phosphatase (U/L)-0.8 ± 10.99-0.5 ± 12.30—
Week 4 of cycle 1 - Aspartate Aminotransferase (U/L)0.2 ± 11.280.1 ± 8.63—
Week 4 of cycle 1 - Gamma Glutamyl Transpeptidase (U/L)0.8 ± 50.890.8 ± 12.41—
Week 4 of cycle 2 - Alanine Aminotransferase (U/L)——1.1 ± 10.68
Week 4 of cycle 2 - Alkaline phosphatase (U/L)——0.9 ± 9.42
Week 4 of cycle 2 - Aspartate Aminotransferase (U/L)——-0.2 ± 12.76
Week 4 of cycle 2 - Gamma Glutamyl Transpeptidase (U/L)——1.3 ± 11.09
Week 4 of cycle 3 - Alanine Aminotransferase (U/L)——-0.4 ± 13.43
Week 4 of cycle 3 - Alkaline phosphatase (U/L)——0.6 ± 10.89
Week 4 of cycle 3 - Aspartate Aminotransferase (U/L)——-1.0 ± 14.73
Week 4 of cycle 3 - Gamma Glutamyl Transpeptidase (U/L)——0.0 ± 9.64
Week 4 of cycle 4 - Alanine Aminotransferase (U/L)——-0.2 ± 10.82
Week 4 of cycle 4 - Alkaline phosphatase (U/L)——0.9 ± 10.75
Week 4 of cycle 4 - Aspartate Aminotransferase (U/L)——-1.6 ± 14.54
Week 4 of cycle 4 - Gamma Glutamyl Transpeptidase (U/L)——1.0 ± 9.59
SecondaryChange From Baseline of Cholesterol, Glucose, Potassium, Sodium, Urea Nitrogen

Safety assessments by evaluating change from baseline of Cholesterol, Glucose, Potassium, Sodium, Urea Nitrogen as per the study schedule

Time frame:
Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)
Reported as:
Mean · mmol/L
Change From Baseline of Cholesterol, Glucose, Potassium, Sodium, Urea Nitrogen
mmol/LBotulinum Toxin APlaceboBotulinum Toxin A Open Label Extension Arm
Week 4 of cycle 1 - Cholesterol (mmol/L)-0.119 ± 0.6477-0.049 ± 0.5400—
Week 4 of of cycle 1 - Glucose (mmol/L)0.317 ± 1.17510.290 ± 0.9429—
Week 4 of of cycle 1 - Potassium (mmol/L)-0.06 ± 0.405-0.09 ± 0.431—
Week 4 of of cycle 1 - Sodium (mmol/L)-0.1 ± 2.39-0.3 ± 2.35—
Week 4 of of cycle 1 - Urea nitrogen (mmol/L)0.01 ± 1.3560.00 ± 1.123—
Week 4 of cycle 2 - Cholesterol (mmol/L)——0.07 ± 0.5910
Week 4 of of cycle 2 - Glucose (mmol/L)——0.086 ± 1.2927
Week 4 of of cycle 2 - Potassium (mmol/L)——0.03 ± 0.391
Week 4 of of cycle 2 - Sodium (mmol/L)——-0.1 ± 2.28
Week 4 of of cycle 2 - Urea nitrogen (mmol/L)——-0.05 ± 1.277
Week 4 of cycle 3 - Cholesterol (mmol/L)——0.021 ± 0.7421
Week 4 of of cycle 3 - Glucose (mmol/L)——0.185 ± 1.5644
Week 4 of of cycle 3 - Potassium (mmol/L)——0.03 ± 0.415
Week 4 of of cycle 3 - Sodium (mmol/L)——0.1 ± 2.44
Week 4 of of cycle 3 - Urea nitrogen (mmol/L)——0.01 ± 1.272
Week 4 of of cycle 4 - Cholesterol (mmol/L)——0.040 ± 0.6614
Week 4 of of cycle 4 - Glucose (mmol/L)——-0.098 ± 1.9131
Week 4 of of cycle 4 - Potassium (mmol/L)——0.08 ± 0.039
Week 4 of of cycle 4 - Sodium (mmol/L)——0.2 ± 1.87
Week 4 of of cycle 4 - Urea nitrogen (mmol/L)——0.06 ± 1.398
SecondaryChange From to Baseline of Bilirubin, Creatinin

Safety assessments by evaluating change from baseline of Bilirubin, Creatinin as per the study schedule

Time frame:
Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)
Reported as:
Mean · μmol/L
Change From to Baseline of Bilirubin, Creatinin
μmol/LBotulinum Toxin APlaceboBotulinum Toxin A Open Label Extension Arm
Week 4 of cycle 1 - Bilirubin (μmol/L)0.05 ± 3.555-0.14 ± 3.597—
Week 4 of cycle 1 - Creatinine (μmol/L)0.52 ± 8.404-0.30 ± 6.556—
Week 4 of cycle 2 - Bilirubin (μmol/L)——-0.12 ± 3.329
Week 4 of cycle 2 - Creatinine (μmol/L)——-0.49 ± 8.550
Week 4 of cycle 3 - Bilirubin (μmol/L)——-0.14 ± 3.283
Week 4 of cycle 3 - Creatinine (μmol/L)——0.06 ± 9.553
Week 4 of cycle 4 - Bilirubin (μmol/L)——0.52 ± 3.203
Week 4 of cycle 4 - Creatinine (μmol/L)——-0.66 ± 9.536
SecondaryChange From Baseline of Erythrocytes

Safety assessments by evaluating change from baseline of Erythrocytes as per the study schedule

Time frame:
Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)
Reported as:
Mean · x10^12 cells/L
Change From Baseline of Erythrocytes
x10^12 cells/LBotulinum Toxin APlaceboBotulinum Toxin A Open Label Extension Arm
Cycle 1-0.002 ± 0.2425-0.038 ± 0.2194—
Cycle 2——0.032 ± 0.2091
Cycle 3——0.063 ± 0.2619
Cycle 4——0.041 ± 0.2716
SecondaryChange From Baseline of Erythrocytes MCV

Safety assessments by evaluating change from baseline of Erythrocytes MCV as per the study schedule

Time frame:
Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)
Reported as:
Mean · fL
Change From Baseline of Erythrocytes MCV
fLBotulinum Toxin APlaceboBotulinum Toxin A Open Label Extension Arm
Cycle 1-0.78 ± 2.615-0.79 ± 2.860—
Cycle 2——-0.38 ± 3.070
Cycle 3——0.53 ± 4.209
Cycle 4——2.18 ± 3.875
SecondaryChange From Baseline of Erythrocyte MCHC, Hemoglobin

Safety assessments by evaluating change from baseline of Erythrocyte MCHC, Hemoglobin as per the study schedule

Time frame:
Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)
Reported as:
Mean · g/dL
Change From Baseline of Erythrocyte MCHC, Hemoglobin
g/dLBotulinum Toxin APlaceboBotulinum Toxin A Open Label Extension Arm
Week 4 of cycle 1 - Erythrocyte MCHC (g/dL)0.32 ± 0.9540.33 ± 1.041—
Week 4 of cycle 1 - Hemoglobin (g/dL)0.02 ± 0.732-0.09 ± 0.740—
Week 4 of cycle 2 - Erythrocyte MCHC (g/dL)——0.16 ± 1.070
Week 4 of cycle 2 - Hemoglobin (g/dL)——0.12 ± 0.638
Week 4 of cycle 3 - Erythrocyte MCHC (g/dL)——-0.12 ± 1.366
Week 4 of cycle 3 - Hemoglobin (g/dL)——-0.21 ± 0.821
Week 4 of cycle 4 - Erythrocyte MCHC (g/dL)——-0.65 ± 1.306
Week 4 of cycle 4 - Hemoglobin (g/dL)——-0.15 ± 0.921
SecondaryChange From Baseline of Lymphocytes/Leukocytes, Monocytes/Leukocytes, Neutrophils/Leukocytes, Basophiles/Leukocytes, Eosinophils/Leukocytes

Safety assessments by evaluating change from baseline of Lymphocytes/leukocytes, Monocytes/leukocytes, Neutrophils/leukocytes, Basophiles/leukocytes, Eosinophils/leukocytes as per the study schedule

Time frame:
Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)
Reported as:
Mean · % of leukocytes
Change From Baseline of Lymphocytes/Leukocytes, Monocytes/Leukocytes, Neutrophils/Leukocytes, Basophiles/Leukocytes, Eosinophils/Leukocytes
% of leukocytesBotulinum Toxin APlaceboBotulinum Toxin A Open Label Extension Arm
Week 4 of cycle 1 - Basophiles/leukocytes (%)0.05 ± 0.6690.14 ± 0.890—
Week 4 of cycle 1 - Eosinophils/leukocytes (%)0.14 ± 1.0900.05 ± 1.292—
Week 4 of cycle 1 - Lymphocytes/leukocytes (%)-0.26 ± 6.724-1.13 ± 5.468—
Week 4 of cycle 1 - Monocytes/leukocytes (%)-0.40 ± 2.337-0.48 ± 2.350—
Week 4 of cycle 1 - Neutrophils/leukocytes (%)0.47 ± 7.6101.41 ± 6.219—
Week 4 of cycle 2 - Basophiles/leukocytes (%)——-0.04 ± 0.837
Week 4 of cycle 2 - Eosinophils/leukocytes (%)——0.13 ± 1.554
Week 4 of cycle 2 - Lymphocytes/leukocytes (%)——0.80 ± 6.802
Week 4 of cycle 2 - Monocytes/leukocytes (%)——-0.04 ± 1.559
Week 4 of cycle 2 - Neutrophils/leukocytes (%)——-0.84 ± 7.660
Week 4 of cycle 3 - Basophiles/leukocytes (%)——-0.25 ± 0.764
Week 4 of cycle 3 - Eosinophils/leukocytes (%)——0.06 ± 1.788
Week 4 of cycle 3 - Lymphocytes/leukocytes (%)——0.82 ± 7.814
Week 4 of cycle 3 - Monocytes/leukocytes (%)——-0.16 ± 1.790
Week 4 of cycle 3 - Neutrophils/leukocytes (%)——-0.47 ± 9.240
Week 4 of cycle 4 - Basophiles/leukocytes (%)——-0.23 ± 0.663
Week 4 of cycle 4 - Eosinophils/leukocytes (%)——-0.26 ± 1.191
Week 4 of cycle 4 - Lymphocytes/leukocytes (%)——1.68 ± 6.869
Week 4 of cycle 4 - Monocytes/leukocytes (%)——0.06 ± 2.434
Week 4 of cycle 4 - Neutrophils/leukocytes (%)——-1.34 ± 7.460
SecondaryChange From Baseline of Systolic and Diastolic Blood Pressure

Safety assessments by evaluating change from baseline of Systolic and Diastolic Blood Pressure as per the study schedule

Time frame:
Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)
Reported as:
Mean · mmHg
Change From Baseline of Systolic and Diastolic Blood Pressure
mmHgBotulinum Toxin APlaceboBotulinum Toxin A Open Label Extension Arm
Week 4 of cycle 1 - Systolic Blood Pressure (mmHg)-0.7 ± 11.13-0.2 ± 10.50—
Week 4 of cycle 1 - Diastolic Blood Pressure (mmHg)-1.0 ± 7.541.3 ± 8.16—
Week 4 of cycle 2 - Systolic Blood Pressure (mmHg)——-0.9 ± 11.66
Week 4 of cycle 2 - Diastolic Blood Pressure (mmHg)——0.0 ± 7.79
Week 4 of cycle 3 - Systolic Blood Pressure (mmHg)——-1.7 ± 12.06
Week 4 of cycle 3 - Diastolic Blood Pressure (mmHg)——-0.4 ± 8.02
Week 4 of cycle 4 - Systolic Blood Pressure (mmHg)——-1.8 ± 13.40
Week 4 of cycle 4 - Diastolic Blood Pressure (mmHg)——-0.2 ± 7.38
SecondaryChange From Baseline of Pulse Rate

Safety assessments by evaluating change from baseline of Pulse rate as per the study schedule

Time frame:
Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)
Reported as:
Mean · bpm
Change From Baseline of Pulse Rate
bpmBotulinum Toxin APlaceboBotulinum Toxin A Open Label Extension Arm
Cycle 1-1.7 ± 10.830.1 ± 10.24—
Cycle 2——1.2 ± 9.11
Cycle 3——2.2 ± 10.73
Cycle 4——0.7 ± 10.73
SecondaryNumber of Participants With Normal and Abnormal Electrocardiogram

Safety assessments by evaluating Electrocardiogram as per the study schedule

Time frame:
Week 4 and last visit of Treatment Cycle 1 (End of Cycle procedures), conducted upon confirmation of eligibility for retreatment, assessed starting 12 weeks post-treatment with 4-weekly evaluations up to a max. of 48 weeks post treatment.
Reported as:
Count of participants · Participants
Number of Participants With Normal and Abnormal Electrocardiogram
ParticipantsBotulinum Toxin A - Normal Baseline Electrocardiogram InterpretationBotulinum Toxin A - Abnormal Baseline Electrocardiogram InterpretationPlacebo - Normal Baseline Electrocardiogram InterpretationPlacebo - Abnormal Baseline Electrocardiogram Interpretation
Cycle 1 Week 4 - Electrocardiogram Interpretation — Normal2235713
Cycle 1 Week 4 - Electrocardiogram Interpretation — Abnormal132238
Cycle 1 End of Cycle Visit - Electrocardiogram Interpretation — Normal1986693
Cycle 1 End of Cycle Visit - Electrocardiogram Interpretation — Abnormal101948

Adverse events

Collected over Up to 60 weeks post first treatment. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Botulinum Toxin A0/266 (0%)1/266 (0.4%)12/266 (4.5%)
Placebo0/89 (0%)1/89 (1.1%)6/89 (6.7%)
Botulinum Toxin A Open Label Extension Arm0/323 (0%)4/323 (1.2%)14/323 (4.3%)
Most frequent serious events
Most frequent serious events
EventBotulinum Toxin APlaceboBotulinum Toxin A Open Label Extension Arm
SyncopeNervous system disorders0/2661/890/323
Foot deformityMusculoskeletal and connective tissue disorders1/2660/890/323
Acute myocardial infarctionCardiac disorders0/2660/891/323
GoitreEndocrine disorders0/2660/891/323
CholecystitisHepatobiliary disorders0/2660/891/323
CholelithiasisHepatobiliary disorders0/2660/891/323
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/2660/891/323
Most frequent other events
Most frequent other events
EventBotulinum Toxin APlaceboBotulinum Toxin A Open Label Extension Arm
HeadacheNervous system disorders10/2662/895/323
NasopharyngitisInfections and infestations2/2663/899/323
Tooth fractureInjury, poisoning and procedural complications0/2662/891/323

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Botulinum Toxin APlaceboTotal
<=18 years000
Between 18 and 65 years23381314
>=65 years33841
Age, Continuous
Age, Continuous(years)Botulinum Toxin APlaceboTotal
Mean52.2 ± 11.2449.4 ± 12.3651.5 ± 11.58
Sex: Female, Male
Sex: Female, Male(Participants)Botulinum Toxin APlaceboTotal
Female24880328
Male18927
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Botulinum Toxin APlaceboTotal
Hispanic or Latino662288
Not Hispanic or Latino20067267
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Botulinum Toxin APlaceboTotal
American Indian or Alaska Native000
Asian415
Native Hawaiian or Other Pacific Islander000
Black or African American25732
White23679315
More than one race123
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Botulinum Toxin APlaceboTotal
United States22579304
Austria411051
Facial Wrinkle Scale at Maximum Frown by Investigator and Subject In-clinic Assessment
Facial Wrinkle Scale at Maximum Frown by Investigator and Subject In-clinic Assessment(Participants)Botulinum Toxin APlaceboTotal
Investigator's In-clinic Assessment — No facial wrinkles000
Investigator's In-clinic Assessment — Mild facial wrinkles000
Investigator's In-clinic Assessment — Moderate facial wrinkles642286
Investigator's In-clinic Assessment — Severe facial wrinkles20267269
Subject's In-clinic Assessment — No facial wrinkles000
Subject's In-clinic Assessment — Mild facial wrinkles000
Subject's In-clinic Assessment — Moderate facial wrinkles702595
Subject's In-clinic Assessment — Severe facial wrinkles19664260
08

Study locations

1 site
  • Tennessee Clinical Research Center
    Nashville, Tennessee 37215, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — This is not decided yet and will be changed accordingly when the decision has been made

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2019 to primary completion in Dec 2019, 7 months.

Results were first posted in Jun 2025, 5 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2019
First posted
Jun 14, 2019
StartActual
Apr 29, 2019
Primary completionActual
Dec 4, 2019
CompletionActual
Dec 22, 2020
Results first posted
Jun 5, 2025
Last update
Jun 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03985982
Lead sponsor
Croma-Pharma GmbH
Responsible party
Sponsor
First posted
Jun 14, 2019
Start date
Apr 29, 2019
Primary completion
Dec 4, 2019
Completion
Dec 22, 2020
Results posted
Jun 5, 2025
Last update
Jun 5, 2025

Study contacts

Jeffrey Adelglass, Dr.
principal investigator · SKINTASTIC Medical
Sue Ellen Cox, Dr.
principal investigator · Aesthetic Solutions P.A.
Michael Gold, Dr.
principal investigator · Tennessee Clinical Research Center
Joely Kaufman-Janette, Dr.
principal investigator · Skin Research Institute LLC
Susan Taylor, Dr.
principal investigator · Perelman Center for Advanced Medicine-University of Pennsylvania
Mark Nestor, Dr.
principal investigator · Center for Clinical and Cosmetic Research
Daniel Mueller, Dr.
principal investigator · Yuvell (Austria)

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Botulinum toxin type A

Start the discussion